Temporal Decline in Sirolimus Elimination Immediately After Pancreatic Islet Transplantation

この論文にアクセスする

この論文をさがす

著者

    • SATO Eriko
    • Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University
    • SHIMOMURA Masahiro
    • Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University
    • MASUDA Satohiro
    • Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University
    • YANO Ikuko
    • Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University
    • KATSURA Toshiya
    • Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University
    • MATSUMOTO Shin-ichi
    • Department of Transplantation and Immunology, Graduate School of Medicine, Kyoto University
    • OKITSU Teru
    • Department of Transplantation and Immunology, Graduate School of Medicine, Kyoto University
    • IWANAGA Yasuhiro
    • Department of Transplantation and Immunology, Graduate School of Medicine, Kyoto University
    • NOGUCHI Hirofumi
    • Department of Transplantation and Immunology, Graduate School of Medicine, Kyoto University
    • NAGATA Hideo
    • Department of Transplantation and Immunology, Graduate School of Medicine, Kyoto University
    • YONEKAWA Yukihide
    • Department of Transplantation and Immunology, Graduate School of Medicine, Kyoto University
    • INUI Ken-ichi
    • Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University

抄録

  Pancreatic islet transplantation is a curable treatment for type 1 diabetes and has been put into practice in various countries. In this study, we analyzed the pharmacokinetic characteristics of sirolimus and tacrolimus in six Japanese patients with pancreatic islet transplants immediately after surgery, and monitored efficacy and toxicity. The patients were treated with immunosuppressive therapy based on the Edmonton protocol, that is, sirolimus and low-dose tacrolimus. Pharmacokinetic analyses were performed using the nonlinear mixed-effects modeling program NONMEM. Large inter- and intra-individual variability was observed in the pharmacokinetics of sirolimus and tacrolimus. A model with increased apparent clearance in the postoperative period explained well the intra-individual variability in the pharmacokinetics of both drugs. The most frequent drug-induced toxicity was a decrease in the white blood cell count, and two of six patients required the administration of granulocyte colony-stimulating factor. Clinical laboratory tests immediately before the transplantation and cytochrome P450 3A5 genotype were not related to the high blood concentrations of sirolimus after the loading dose. From these results, the apparent clearance of sirolimus and tacrolimus might temporally decline immediately after pancreatic islet transplantation. A high trough concentration of sirolimus might increase the risk of hematological toxicy, and adjustment of the dosage for immunosuppressive treatment will be necessary in Japanese patients.<br>

収録刊行物

  • Drug metabolism and pharmacokinetics  

    Drug metabolism and pharmacokinetics 21(6), 492-500, 2006-12-25 

    The Japanese Society for the Study of Xenobiotics

参考文献:  29件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  3件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018659035
  • NII書誌ID(NCID)
    AA1162652X
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    13474367
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ